Back
Zoetis faces securities fraud class action over 2025-2026 disclosures

Zoetis faces securities fraud class action over 2025-2026 disclosures

A new plaintiff-side release says repeated disclosures from August 2025 through May 2026 drove analyst downgrades and sharp stock declines, culminating in a 21.5% one-day drop after first-quarter 2026 results.

Fact Check
Multiple independent plaintiff-side releases (KTMC, Gross Law Firm) and litigation firm case descriptions (Scott+Scott) confirm a filed securities fraud class action against Zoetis in the S.D.N.Y. The complaint alleges corrective disclosures over four events from Aug 5, 2025 through May 7, 2026 — matching the claim's 'August 2025 through May 2026' framing — with a 21.5% single-day stock drop on May 7, 2026 following Q1 2026 results showing Companion Animal declines. The 21.5% figure and Q1 2026 timing are consistently reported across sources, and Zoetis's own IR page confirms the Q1 2026 earnings event. The only minor discrepancy is that the formal class period begins January 14, 2025, while the disclosure/downgrade window is August 2025–May 2026; this is consistent with the claim rather than contradictory.
Summary

Zoetis Inc. is facing a securities fraud class action covering investors who purchased ZTS securities between January 14, 2025 and May 6, 2026, with a July 27, 2026 deadline to seek appointment as lead plaintiff. In addition to earlier allegations that the company misled investors about Librela, Simparica Trio, Apoquel and Cytopoint, a new release from SueWallSt, powered by Levi & Korsinsky LLP, says Wall Street’s view of Zoetis deteriorated over four alleged corrective disclosures between August 5, 2025 and May 7, 2026. The release says the company’s Companion Animal segment, which generated about 70% of total revenue, had been central to growth expectations, supported by management’s commentary on dermatology market expansion, Simparica Trio’s market position and Librela’s launch trajectory. It alleges those assumptions were later undermined by signs of veterinarian caution following an FDA Dear Veterinarian letter in December 2024, growing competitive pressure from Elanco products including Credelio Quattro and Zenrelia, weaker prescription trends, and reduced guidance. Zoetis shares were described as falling 3.8% on August 5, 2025, 13.8% on November 4, 2025, 2.35% on February 12, 2026, and 21.5% on May 7, 2026, with the final drop equaling $23.91 per share. The earlier filed case in the Southern District of New York remains identified as City of Ann Arbor Retiree Health Care Benefit Plan & Trust v. Zoetis Inc., No. 26-cv-04401, while the newer release frames the alleged investor harm through the lens of analyst downgrades and repriced growth expectations.

Terms & Concepts
  • lead plaintiff: The investor appointed by the court to represent the proposed class and help direct the litigation.
  • securities fraud class action: A lawsuit alleging investors were harmed by materially false or misleading public statements or omissions.
  • corrective disclosures: Company disclosures that allegedly reveal previously hidden problems and can trigger stock-price declines.